Stock ABBV ABBVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up
ChatBot Beta

Press Releases AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX
Other stock markets
 02:36:47 2025-02-11 pm EST 		5-day change 1st Jan Change
191.63 USD +0.68% Intraday chart for AbbVie Inc. +0.71% +7.66%
Feb. 07 Abbvie Says FDA Approves Treatment For Intra-Abdominal Infections RE
Feb. 07 AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo DJ

Press Releases

Search
See the results
AbbVie - U.S. FDA Approves EMBLAVEO for the Treatment of Adults with Complicated Intra-Abdominal Infections with Limited or No Treatment Options
Feb. 10
 AQ
U.S. FDA Approves EMBLAVEO™ (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options
Feb. 07
 PR
Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle Campaign
Feb. 07
 AQ
Allergan Aesthetics Invites Consumers to Join the Faces of Natrelle® Campaign
Feb. 06
 PR
AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
Feb. 03
 AQ
AbbVie : Reports Full Year and Fourth Quarter 2024 Financial Results
Jan. 31
 PU
AbbVie: Q4 Earnings Snapshot
Jan. 31
 AQ
Allergan Aesthetics launches new AA Signature Program at IMCAS 2025 to redefine patient-centric, multimodal treatment plans
Jan. 29
 PR
Allergan Aesthetics unveils new AA Signature Program and immersive booth at IMCAS World Congress 2025
Jan. 24
 PR
AbbVie Completes Acquisition of Nimble Therapeutics
Jan. 23
 PR
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
Jan. 23
 PR
AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan. 09
 PR
CoolMonth is Back with Deals on CoolSculpting Elite by Allergan Aesthetics
Jan. 08
 AQ
CoolMonth is Back With Deals on CoolSculpting® Elite by Allergan Aesthetics
Jan. 07
 PR
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
Jan. 06
 AQ
AbbVie to Host Full-Year and Fourth-Quarter 2024 Earnings Conference Call
Jan. 03
 PR
AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline
Dec. 19
 AQ
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Dec. 16
 AQ
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
Dec. 13
 PR
AbbVie Completes Acquisition of Aliada Therapeutics
Dec. 11
 PR
AbbVie - Investigational Epcoritamab Combination Therapy Shows High Response Rates in Clinical Trial of Patients with Relapsed or Refractory Follicular Lymphoma
Dec. 09
 AQ
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
Dec. 09
 PR
AbbVie to Present at Citi's 2024 Global Healthcare Conference
Nov. 25
 PR
AbbVie Receives European Commission Approval of ELAHERE for the Treatment of Platinum-Resistant Ovarian Cancer
Nov. 19
 AQ
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
Nov. 18
 PR
Become a member to access more news.
100% Free Registration
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. News AbbVie Inc.
  5. Press Releases